A First-in-Human, Randomised, Double Blind, Placebo Controlled, Single and Multiple Ascending Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AJM347 in Healthy Male Caucasian and Japanese Subjects in the Fasted and Fed State

Trial Profile

A First-in-Human, Randomised, Double Blind, Placebo Controlled, Single and Multiple Ascending Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AJM347 in Healthy Male Caucasian and Japanese Subjects in the Fasted and Fed State

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 25 May 2017

At a glance

  • Drugs AJM 347 (Primary)
  • Indications Unspecified
  • Focus Adverse reactions; First in man
  • Sponsors EA Pharma
  • Most Recent Events

    • 17 May 2017 Planned End Date changed from 1 Nov 2018 to 1 Mar 2018.
    • 17 May 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Aug 2018.
    • 05 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top